{"entity":{"id":"paper-gross-eshhar-chimeric-receptor-pnas-1989","kind":"paper","name":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","aka":[],"tldr":"The paper that invented the CAR. A T cell was given the business end of an antibody, and it killed what the antibody recognised without needing the immune system's usual permission step.","summary":"Zelig Eshhar's group at the Weizmann Institute of Science asked whether the specificity of a T cell could be designed rather than selected. They built chimeric T-cell receptor genes in which the variable domains of the heavy and light chains of an anti-trinitrophenyl antibody (SP6) were spliced to the constant regions of the T-cell receptor alpha or beta chain, and expressed them in a cytotoxic T-cell hybridoma.\n\nThe transfectants expressed a functional receptor carrying the antibody's idiotope, and responded to trinitrophenyl-bearing targets without major histocompatibility complex restriction, killing them and producing interleukin-2 across strain and species barriers. They also responded to immobilised trinitrophenyl-protein conjugates, which means cellular processing and presentation were bypassed entirely. Because the binding site of this particular antibody lies almost wholly in the heavy chain, a construct containing only the heavy-chain variable domain fused to either constant region was enough.\n\nEshhar called the construct a T-body. Everything that followed, the single-chain variable fragment format, the CD28 and 4-1BB costimulatory domains added by Michel Sadelain, Carl June and Dario Campana, and the manufacturing that turns the idea into a product, is built on this experiment.","asOf":"2026-09-25","links":[{"label":"PNAS 1989","url":"https://doi.org/10.1073/pnas.86.24.10024"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/2513569/"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["weizmann"],"pathways":[],"terms":[],"trials":[],"people":["zelig-eshhar"],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":[],"journals":["pnas"],"dependsOn":[],"notes":[],"journal":"Proceedings of the National Academy of Sciences","year":1989,"doi":"10.1073/pnas.86.24.10024","pmid":"2513569","authors":"Gross G, Waks T, Eshhar Z","paperType":"basic","findings":["Chimeric genes joining antibody variable domains to T-cell receptor constant domains produced a functional surface receptor on a cytotoxic T-cell hybridoma.","The chimeric receptor conferred non-MHC-restricted killing and interleukin-2 production against hapten-bearing targets across strain and species barriers.","Transfectants responded to immobilised hapten-protein conjugates, bypassing antigen processing and presentation altogether.","A construct carrying only the heavy-chain variable domain fused to the alpha or beta constant region was sufficient in this system."],"whatItMeans":"Every approved CAR-T product descends from this design. It is the reason a T cell can be pointed at CD19 or BCMA at all, and the reason the question of what to point it at in solid tumours is a question about antigens rather than about the receptor.","caveats":["A model antigen (trinitrophenyl) in a hybridoma, not a tumour antigen in a patient. The construct had no costimulatory domain, so first-generation CARs of this kind proved too weak in the clinic; the additions that made CAR-T work came a decade or more later from other groups."],"changedPractice":true},"route":"/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"institution":[{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/"}],"person":[{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"journal":[{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/"}]}}